Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05425940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05425940 · ClinicalTrials.gov record · last posted 2026-07-17

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Study acronym: STELLAR-303
StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started2022-09-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2022-06-16; most recent amendment 2026-07-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-07-02
Status change Recruiting→Active, Not Recruitingv26
Trial Details
NCT Number NCT05425940
Lead Sponsor Exelixis
Conditions Colorectal Cancer
Enrollment 901 participants
Start Date 2022-09-07
Primary Completion 2026-06-16 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17